Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 57Myelodysplastic Syndromes 32Leukemia, Myelomonocytic, Chronic 15Leukemia 15Recurrence 8Multiple Myeloma 8Neoplasms 6Primary Myelofibrosis 5Myeloproliferative Disorders 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma, Follicular 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm, Residual 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid 2Hodgkin Disease 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2

Interventions

venetoclax 1magrolimab 1cc-486 1Mitoxantrone 1Etoposide 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Myeloid Malignancies × Azacitidine × Clear all
NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Gilead Sciences

Phase 2 Terminated
54 enrolled 26 charts

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡